# US 8,278,061 B2 · Polymorphisms in the EGFR pathway as markers for cancer treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,061 B2
- Document ID: US8278061B2
- Status: Granted
- Kind: B2
- Application number: 12/523,517
- Filed: 2008-01-17
- Published: 2010-07-08
- Granted: 2012-10-02
- Earliest claimed: 2007-01-18
- Assignees: University of Southern California
- Inventors: Heinz-Josef Lenz; Wu Zhang
- Web page: https://patentgrep.com/patent/US8278061B2

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 35/00: Antineoplastic agents
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides compositions and methods for identifying patients for single agent anti-EGFR therapy. The methods comprise determining the genomic polymorphism present in a predetermined region of a gene of interest and correlating the polymorphism to the predictive response. Patients identified as responsive are then treated with the appropriate therapy.

## Claims

### Claim 1

A method for determining whether a human colorectal cancer patient is likely or less likely responsive to a single agent anti-EGFR antibody based therapy selected from Cetuximab or an antibody that binds to the same epitope that Cetuximab binds, comprising screening a suitable cell or tissue sample isolated from said patient for the genetic polymorphism of COX-2 T8473C SNP wherein the presence of the genetic polymorphism of (C/C) for COX-2 T8473C SNP indicates the patient is likely responsive to said single agent anti-EGFR antibody based therapy and wherein the absence of the genetic polymorphism of (C/C) for COX-2 T8473C SNP indicates the patient is less likely responsive to said single agent anti-EGFR antibody based therapy.

### Claim 2 (depends on 1)

The method of claim 1, wherein the colorectal cancer is a metastatic or non-metastatic cancer selected from the group consisting of rectal cancer, colorectal cancer, and colon cancer.

### Claim 3 (depends on 1)

The method of claim 1, wherein the patient is suffering from metastatic colorectal cancer.

### Claim 4 (depends on 1)

The method of claim 1, wherein the presence of the genetic polymorphism of (C/C) for COX-2 T8473C SNP indicates the patient is likely responsive to said single agent anti-EGFR antibody based therapy.

### Claim 5 (depends on 1)

The method of claim 1, wherein the absence of the genetic polymorphism of (C/C) for COX-2 T8473C SNP indicates the patient is less likely responsive to said single agent anti-EGFR antibody based therapy.
